Crescent Biopharma Stock Surges 85%, With A 6-Day Winning Spree
Crescent Biopharma (CBIO) – a developer of glycomimetic drugs targeting acute myeloid leukemia – hit a 6-day winning streak, with cumulative gains over this period amounting to 85%. The company’s market cap has surged by about $270 Mil over the last 6 days and currently stands at $588 Mil.
Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
But here is the interesting part. You are reading about this 85% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio is based on an architecture that includes such signals.
Returns vs S&P 500
- How To Earn 9.2% Yield While Waiting to Buy LLY 30% Cheaper
- Could Accenture Stock’s Cash Flow Spark the Next Rally?
- Years of Rewards: $35 Bil From Charter Communications Stock
- McDonald’s Stock Capital Return Hits $35 Bil
- Palo Alto Networks Stock at Support Zone – Bargain or Trap?
- Super Micro Computer Stock Pulls Back to Support – Smart Entry?
The following table summarizes the return for CBIO stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | CBIO | S&P 500 |
|---|---|---|
| 1D | 5.2% | 0.7% |
| 6D (Current Streak) | 85.1% | 0.3% |
| 1M (21D) | 72.7% | -3.5% |
| 3M (63D) | 66.6% | -4.7% |
| YTD 2026 | 62.9% | -3.9% |
| 2025 | 16.4% | |
| 2024 | 23.3% | |
| 2023 | 24.2% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 127 S&P constituents with 3 days or more of consecutive gains and 24 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 108 | 17 |
| 4D | 6 | 5 |
| 5D | 5 | 2 |
| 6D | 0 | 0 |
| 7D or more | 8 | 0 |
| Total >=3 D | 127 | 24 |
Key Financials for Crescent Biopharma (CBIO)
Last 2 Fiscal Years:
| Metric | FY- | FY2025 |
|---|---|---|
| Revenues | $- | $10.8 Mil |
| Operating Income | $- | $-152.6 Mil |
| Net Income | $- | $-153.9 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ3 | 2025 FQ4 |
|---|---|---|
| Revenues | $0 | $10.8 Mil |
| Operating Income | $-25.9 Mil | $-91.5 Mil |
| Net Income | $-24.6 Mil | $-92.4 Mil |
While CBIO stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.